Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (321-330 of 441) with videos related to

Pageof 45
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapyPhilippe Sultanik, Vincent Mallet, Sylvie Lagaye, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Journal of Hepatology|July 20, 2014
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis CJean-Pierre Bronowicki, Vlad Ratziu, Adrian Gadano, et al.
HIV Medicine|August 17, 2021
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysisMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Gastroenterology|February 3, 2005
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infectionSébastien Dharancy, Mathilde Malapel, Gabriel Perlemuter, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
Clinical Diabetes and Endocrinology|April 24, 2024
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohortArnaud Nze Ossima, Angélique Brzustowski, Valérie Paradis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2017
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE StudyVictor de Lédinghen, Claire Laforest, Christophe Hézode, et al.
Journal of Hepatology|March 28, 2024
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetesLaurent Castera, Philippe Garteiser, Cédric Laouenan, et al.
Pageof 45

Showing results (321-330 of 441) with videos related to

Sort By:
Pageof 45
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapyPhilippe Sultanik, Vincent Mallet, Sylvie Lagaye, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialZobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Journal of Hepatology|July 20, 2014
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis CJean-Pierre Bronowicki, Vlad Ratziu, Adrian Gadano, et al.
HIV Medicine|August 17, 2021
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysisMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.
Gastroenterology|February 3, 2005
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infectionSébastien Dharancy, Mathilde Malapel, Gabriel Perlemuter, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
Clinical Diabetes and Endocrinology|April 24, 2024
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohortArnaud Nze Ossima, Angélique Brzustowski, Valérie Paradis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2017
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE StudyVictor de Lédinghen, Claire Laforest, Christophe Hézode, et al.
Journal of Hepatology|March 28, 2024
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetesLaurent Castera, Philippe Garteiser, Cédric Laouenan, et al.
Pageof 45